Revlimid is a prescription drug used to treat certain types of blood cancers, including multiple myeloma. There are no known foods that interact with Revlimid, but there may be certain foods to ...

智通财经APP获悉，百时美施贵宝(BMY.US)第四季度营收为123亿美元，超过市场预期，其中Eliquis和Revlimid的销售超过预期。最近上市的两种药物——心脏 ...

Bristol-Myers Squibb's blood cancer blockbuster Revlimid is finally facing generic competition in the US, which will eat into revenues from a drug that made a massive $12.8 billion in sales last year.

FDA approved Amneal's generic lenalidomide capsules, referencing Celgene's Revlimid, for manufacturing and sale starting in 2026. Amneal launched mesalamine 800 mg delayed-release tablets for ...

NHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after a stem cell transplant, after new guidance from NICE.

Jefferies backs Lupin, Zydus, and Biocon amid shifting US pharma market shares. Discover why these stocks are set to shine.

Bristol-Myers Squibb has shown exceptional success in addressing challenges directly related to the introduction of generic versions of Revlimid and Sprycel. So, the gem in its oncology franchise ...

The pharma sector export data for fourth quarter has been released. According to Phillip Capital, the latest export data ...

In the face of looming revenue decline from blood cancer medication Revlimid, Indian pharma companies Natco Pharma and Dr. Reddy's Laboratories are shifting their focus to a promising new frontier ...

The significant fall in EBITDA margins reflects the deteriorating profitability in the absence of Revlimid , a key drug that had been a strong revenue contributor in previous quarters. The steep ...

The brokerage is optimistic about the pharmaceutical company's proactive strategies to lessen the effects of the patent expiration for its blockbuster drug Revlimid in 2026. The brokerage noted ...